Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

TP53 signature predicts survival outcome in triple-negative breast cancer with neoadjuvant chemotherapy

ABSTRACT: In the study presented here, a consecutively operated, well-defined cohort of 30 triple-negative breast cancer cases with neoadjuvant chemotherapy, followed up more than five years, was used to acquire TP53 signature composed of a total of 33 genes. Combining the response to NAC and the TP53signature score in triple-negative breast cancer was able to predict an unfavorable prognosis.

ORGANISM(S): Homo sapiens

PROVIDER: GSE190275 | GEO | 2021/12/10

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

TP53 signature predicts survival outcome in triple-negative breast cancer with neoadjuvant chemotherapy

Project description:TP53 signature predicts survival outcome in triple-negative breast cancer with neoadjuvant chemotherapy

| PRJNA786568 | ENA

Gene expression-based, individualized outcome prediction for surgically treated pancreatic cancer patients

Project description:Individualized outcome prediction classifiers were successfully constructed through expression profiling of a total of 8,644 genes in 20 pancreatic cancer cases, which had been consecutively operated.

2024-11-02 | GSE246880 | GEO

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy

Project description:Triple negative breast cancer is a heterogeneous disease with distinct molecular subtypes that differentially respond to chemotherapy and targeted agents. The purpose of this study was to explore the clinical relevance of Lehmann triple negative breast cancer subtypes by identifying any differences in response to neoadjuvant chemotherapy among them.

2017-11-17 | GSE106977 | GEO

An immunological signature to predict outcome in patients with triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy

Project description:When triple-negative breast cancer (TNBC) patients have residual disease after neoadjuvant chemotherapy (NACT), they have a high risk of metastatic relapse. With immune infiltrate in TNBC being prognostic and predictive of response to treatment, our aim was to develop an immunologic transcriptomic signature using post NACT samples to predict relapse.

2022-09-20 | GSE185507 | GEO

Multi-Omics molecular subtyping based on commensal microbiome predicts molecular characteristics and therapeutic response in Triple-Negative Breast Cancer [scRNA-seq]

Project description:We thoroughly analyzed the molecular subtyping of Triple-Negative Breast Cancer and its different manifestations, and located T cells and Tumor cells related to the survival of breast cancer through single cell sequencing and space transcriptome according to our score, and finally investigated their relationship with the therapeutic efficacy, providing a scientific basis for the treatment of triple negative breast cancer.

2024-05-17 | GSE252175 | GEO

Tissue microRNA signatures to predict breast cancer recurrence in young women aged under 35 years old

Project description:Identification for microRNA signatures to predict breast cancer recurrence in young women were performed through expression profiling of a total 2565 miRNAs in 45 samples diagnosed as invasive ducatal carcinoma of no special type (NST) cases which had been consecutively operated on within a defined short period of time.

2017-11-22 | GSE97811 | GEO

Multi-Omics molecular subtyping based on commensal microbiome predicts molecular characteristics and therapeutic response in Triple-Negative Breast Cancer [Spatial Transcriptome seq]

2024-05-17 | GSE252176 | GEO

A 5-gene signature predicts outcome in women with hormone receptor-negative early breast cancer treated with chemoterapy.

Project description:Hormone-receptor negative (HR-) breast cancer accounts for approximately one third of all breast tumors and has a worse prognosis compared with hormone receptor-positive disease. Their unfavorable outcome and the lack of hormonal receptors determine the use of adjuvant chemotherapy as part of the standard treatment for these tumors. However, a significant proportion of patients relapse after receiving adjuvant chemotherapy. Classical prognostic factors such as tumor size, lymph node status and grade of differentiation do not suffice to identify patients with a higher risk of relapse. In the last decade, gene profiling has allowed the description of signatures with prognostic value in hormone receptor-positive tumors, but similar information is scarce in HR- disease. Reliable identification of poor-prognosis patients would be important to offer participation in clinical trials with new drugs and to modify follow-up schedules. In this study, we assessed gene expression with quantitative polymerase-chain reaction (RT-qPCR) in HR- early stage breast cancer. RNA was isolated from formalin-fixed paraffin-embedded (FFPE) tissue. Our purpose was to identify a gene signature related to outcome.

2016-02-01 | GSE33669 | GEO

Response to Neoadjuvant Chemotherapy in Triple Negative Breast tumors.

Project description:In a cohort study of 7 women with primary invasive breast cancer, we obtained a tumor specimen before (biopsy) and after (tumorectomy) 4 cycles of NAC with epirubicine and cyclophosphamide, followed by 4 cycles of taxanes. Total RNA was extracted from tumor specimens and the whole transcriptome was quantified with Affymetrix HuGene1.1ST. Molecular functions changing during chemotherapy were searched. Whole genome expression of triple negative breast cancer tissues were measured before and after four cycles neoadjuvant chemotherapy

2016-03-24 | E-GEOD-43816 | biostudies-arrayexpress

Hypoxanthine phosphoribosyl transferase 1 is upregulated, predicts clinical outcome and controls gene expression in breast cancer

Project description:Hypoxanthine phosphoribosyl transferase 1 (HPRT1) is traditionally believed to be a housekeeping gene; however, recent reports suggest that it is upregulated in several cancers and associates with clinical outcome. Like several cancer testis (CT) genes, HPRT1 is found on chromosome X, and encodes the HPRT enzyme, which functions in recycling nucleotides to supply for DNA and RNA synthesis in actively dividing cells. Here, we have used genome wide expression to interrogate its expression across all known cancer types and elucidated its functional role in breast cancer. We observed elevated HPRT1 RNA levels in malignant tissues when compared to normal controls, indicating its potential as a diagnostic and prognostic marker. Further, in breast cancer, subtype specific analysis showed that its expression was highest in basal and triple-negative breast cancer, and HPRT1 knockdown in breast cancer cells suggested that HPRT1 positively regulates genes specific to cellular and DNA repair pathways. Collectively, our results essentially highlight the importance and change the way HPRT1’s function is studied in biology, and warrants careful examination of its role in cancer.

2020-07-15 | GSE149768 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data